Kaskela Law LLC  is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) (“Eliem”) on behalf of the company’s shareholders.

The investigation seeks to determine whether Eliem issued false and misleading statements and/or failed to disclose material facts to investors in connection with recent corporate actions, thereby violating the securities laws and causing harm to the company’s shareholders.

Eliem shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (888) 715 – 1740 or (484) 229 – 0750, or by completing the form on this page, for additional information about this investigation and their legal rights and options.